Introduction:

Although modern therapies for cancer have improved life expectancy, the management of disease and improvement of quality of life (QoL) of patients, especially managing cancer-related pain and chronic fatigue syndrome are still limited. We demonstrate the efficacy of a combined therapy to treat cancer patients suffering from CFS. The effects of a combined therapy in cancer patients suffering from CFS was evaluated. NK cells were stimulated, additional tumour treatment together with targeted radiofrequency therapy (Oncothermia).

Methods:

SIXTY patients with CFS (due to suffering from any type of cancer) were recruited, (according to the Centres for Disease Control 1994 criteria) attending an outpatient specialist CFS service for controlled pilot study. A total of 25 participants were given oral BioBran (MGN-3-Arabinoxylane) (also known as Lentin Plus 1000), + Oncothermia, for six months, equivalent control group has not received this complex (BioBran + Oncothermia) treatment, they received chemo-,radiotherapy treatment.

Results:

The whole body pH status showed strong tissue acidity before the treatment, but the BioBran group changed the tissue pH status. The most important finding was that the average of CFQ score was significantly reduced after the treatment, and in control group the CFQ scores did not change significantly.

Conclusion:

The findings support a specific therapeutic effect of the complex BioBran+ Oncothermia therapy in CFS of cancer patients improving their QoL, enhancing NK activity in synergy.